戻る Agenda
Outcomes, Endpoints, and Methods Supporting Oncology and Alzheimer Therapies
Session Chair(s)
Brad Sanderson, MHS
Senior Scientific Advisor
Signant Health, United States
This session will provide an overview of past challenges and future opportunities for outcomes research in the Oncology and Alzheimer therapy areas. This will include an update on the state of eCOA and the use of connected devices inside oncology clinical trials as well as a review of existing and future endpoints that could be relevant for immunotherapies. The session will also discuss the eCOA led methodological improvements that are positively supporting Alzheimer clinical trials.
Learning Objective : Describe the use of eCOA and connected health devices inside oncology clinical trials, areas of controversy and opportunity; Discuss current challenges in Alzheimer clinical trials - traditional approaches to eCOA implementation with central oversight; Identify Current challenges associated with measuring c the effects of immunotherapies with existing metrics and proposed metrics to measure outcomes into the future.
Speaker(s)
eCOA and Connected Devices for Supporting Oncology Patients in Clinical Trials
Brad Sanderson, MHS
Signant Health, United States
Senior Scientific Advisor
Measuring and Understanding the Outcomes of Immunotherapies in Oncology
Imad Al-Dakkak, DMD, MPA, MPH
Alexion Pharmaceuticals, Inc., United States
Associate Director